Bristol-Myers Reaches Deal to Continue Selling Abilify

Today is a good day for Bristol-Myers Squibb (BMY) which is one of my top Blue Chip Growth stocks. The healthcare company reached a deal with Japan’s Otsuka Pharmaceutical to continue selling the antidepressant Abilify in the U.S. until 2015.

BMY brought in nearly $2 billion last year from Abilify. The deal also lets Otsuka sell some of Bristol-Myers’ drugs.

This is great news for Bristol-Myers. The company also reiterated its 2009 EPS forecast of $1.85 to $2.00. Bristol-Myers also said that the new deal with lift profitability in 2013 and 2014. The stock is an outstanding buy.

More Louis Navellier

Twitter

Facebook

RSS Feed

Little Book

InvestorPlace Network

InvestorPlace.com

https://orders.investorplace.com/chain?cid=MKT427092&eid=MKT473286&encryptedSnaid=&snaid=&step=start